Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.


CDC Resources: Infection

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Infection.  ‚Äč

The information provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.
 

Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2
Information regarding the community use of cloth masks to control the spread of SARS-CoV-2.

Toolkit for Healthcare Providers
Guidance and tools to help clinicians make decisions, protect patients and employees, and communicate with their communities.

Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic
This guidance has been updated based on currently available information about COVID-19 and the current situation in the United States. 

SARS-CoV-2 Reinfection Criteria
The CDC has released new web content that outlines criteria on COVID-19 cases that should be assessed for suspected reinfection with SARS-CoV-2. The criteria outlines standards that laboratory tests should meet when evaluating specimens for reinfection. CDC also issued a protocol intended to provide state and local health departments with a standardized framework and toolkit for investigating suspected cases of SARS-CoV-2 reinfection.

Strategies for Optimizing the Supply of Facemasks
Information regarding strategies for optimizing the supply of facemasks.

Late Sequelae of COVID-19
Information on late sequelae of COVID-19. 

COVID-19 Science Updates
To help inform CDC’s COVID-19 Response, as well as to help CDC staff stay up to date on the latest COVID-19 research, the Response’s Office of the Chief Medical Officer has collaborated with the CDC Office of Library Science to create a series called COVID-19 Science Update.

COVID-19 Science Updates (Edition 70)
To help inform CDC’s COVID-19 Response, as well as to help CDC staff stay up to date on the latest COVID-19 research, the Response’s Office of the Chief Medical Officer has collaborated with the CDC Office of Library Science to create a series called COVID-19 Science Update.

COVID-19 Webinar & Partner Calls Videos
This is a link to the CDC COVID-19 external resource to COVID-19 webinars and partner calls.

New Variant Strain
This is a link to the CDC COVID-19 external resource regarding implications of the emerging SARS-CoV-2 Variant VUI 202012/01.

Summary for Healthcare Facilities: Strategies for Optimizing the Supply of PPE during Shortages
This is a link to the CDC COVID-19 external resource regarding strategies for optimizing the supply of PPE during shortages.

COVID Data Tracker 
This is a link to the CDC COVID-19 external resource where users can monitor the latest data for any county’s hospital admissions and occupied hospital and ICU beds in the COVID Data Tracker. Users can also search county data to find the latest hospital data, cases, deaths, and more.

Project Firstline Resources
This is a link to the CDC COVID-19 external resource. The Project Firstline website just expanded and it’s now easier than ever to stay up to date on the latest information from CDC’s infection control training collaborative. 

Strategies for Optimizing the Supply of N95 Respirators
This document offers a series of strategies or options to optimize supplies of disposable N95 filtering facepiece respirators (commonly called “N95 respirators”) in healthcare settings when there is limited supply. This guidance has been updated to include clarifications on use of facemasks as a crisis capacity strategy.

Emerging Variants
This link covers new variants of the virus that causes COVID-19.

Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19
This link covers interim guidance on duration of isolation and precautions for adults with COVID-19.

Updated Discontinuation of Transmission-Based Precautions and Disposition of Patients with SARS-CoV-2 Infection in Healthcare Settings 
This is a link to the CDC external resources regarding patients who are severely immunocompromised could remain infectious more than 20 days after symptom onset.  Consultation with infectious diseases specialists is recommended; use of a test-based strategy for determining when to discontinue Transmission-Based Precautions could be considered.

Options to Reduce Quarantine for Contacts of Persons with SARS-CoV-2 Infection Using Symptom Monitoring and Diagnostic Testing
This is a link to the CDC external resources regarding the options to reduce quarantine for contacts of persons with SARS-CoV-2 infection using symptom monitoring and diagnostic testings. 

Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination
This is a link to the CDC external resources regarding updated healthcare infection prevention and control recommendations in response to COVID-19 vaccination.

CDC COVID-19 Resource: Scientific Brief: SARS-CoV-2 Transmission
This scientific brief has been updated to reflect that although how we understand transmission occurs has shifted, the ways to prevent infection with this virus have not.  Modes of SARS-CoV-2 transmission are categorized here as inhalation of virus, deposition of virus on exposed mucous membranes, and touching mucous membranes with soiled hands contaminated with virus. All prevention measures that CDC recommends remain effective for these forms of transmission. 

CDC COVID-19 Resource: COVID-19 Science Update released: April 23, 2021 Edition 86
To help inform CDC’s COVID-19 Response, as well as to help CDC staff stay up to date on the latest COVID-19 research, the Response’s Office of the Chief Medical Officer has collaborated with the CDC Office of Library Science to create a series called COVID-19 Science Update.

CDC COVID-19 Resource: Post-COVID Conditions: Information for Healthcare Providers
Some patients who have been infected with SARS-COV-2 have new, recurring, or ongoing symptoms and clinical findings more than four weeks after infection, sometimes after initial symptom recovery. Post-COVID conditions can occur in patients who had varying degrees of illness during acute infection, including those who had mild or asymptomatic infections.  Medical and research communities are still learning about these post-acute symptoms and clinical findings.

Clinical Considerations: Making Masks for the Workplace: Interim Guidance from NIOSH on New Masks Which Build Upon the ASTM
NIOSH recommends a new standard in masks, called Workplace Performance and Workplace Performance Plus masks, for workplaces. Manufacturing masks that comply with the new NIOSH criteria can help protect people in the workplace from SARS-CoV-2, the virus that causes COVID-19. These masks cannot be used as a replacement for respiratory protection when it is needed.
 
Clinical Considerations: NIOSH-approved Respirators
The supply and availability of NIOSH-approved respirators have increased  significantly over the last several months. Healthcare facilities should not be using crisis capacity strategies at this time and should promptly resume conventional practices. Check the NIOSH Certified Equipment List to identify all NIOSH-approved respirators.
 
Science Brief: COVID-19 Vaccines and Vaccination
In this scientific brief, we summarize evidence available through May 19, 2021, for the currently authorized COVID-19 vaccines (administered according to the recommended schedules) and additional considerations used to inform public health recommendations for fully vaccinated people, including:

  • Vaccine efficacy and effectiveness against SARS-CoV-2 infection
  • Vaccine performance against emerging SARS-CoV-2 variant viruses
  • Impact of other prevention measures in the context of vaccination

 
COCA Call: Underlying Medical Conditions and Severe COVID-19: Evidence-based Information for Healthcare Providers
During this COCA Call, presenters updated clinicians on the underlying medical conditions associated with severe COVID-19, described the methods used to rate the evidence linking conditions to severe COVID-19, reviewed the evidence on risk for conditions included, and provided resources for healthcare providers caring for patients with underlying medical conditions.
 
COCA Call: Underlying CDC Working Group’s Technical Report on Myocarditis
The VaST session on May 17, 2021, included several presentations on myocarditis following mRNA vaccines, from the Department of Defense (DoD), the Vaccine Adverse Event Reporting System (VAERS), and Vaccine Safety Datalink (VSD). There were also brief updates from the Veteran’s Administration (VA) and the Clinical Immunization Safety Assessment (CISA) groups about their plans for future investigation of myocarditis.

How to talk to your patients about COVID-19 vaccination
Healthcare professionals are patients’ and parents’ most-trusted source of information on vaccines. Your answers to their questions matter and will help them make an informed decision about getting a COVID-19 vaccination for themselves or their children.
 
Whether you have these discussions with your patients during an in-person office or hospital encounter, through messages on your patient portal, at a telemedicine visit, or during consultation in your pharmacy, your strong vaccine recommendation is the most important part of the conversation.
 
Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance
Post-COVID conditions are associated with a spectrum of physical, social, and psychological consequences, as well as functional limitations that can present substantial challenges to patient wellness and quality of life. To inform the interim clinical guidance presented here, the CDC obtained individual expert perspectives on the evaluation and management of post-COVID conditions.
 
COCA Call: Evaluating and Caring for Patients with Post-COVID Conditions
The Clinician Outreach and Communication Activity (COCA) held a call Thursday, June 17, 2021, from 2:00–3:00 p.m. (Eastern Time). During this COCA Call, clinicians learned about CDC’s new interim guidance which provides a framework for healthcare providers in their initial assessment, evaluation, management, and follow-up of persons with possible post-COVID conditions.
 
COVID-19 Science Update
To help inform CDC’s COVID-19 Response, as well as to help CDC staff stay up to date on the latest COVID-19 research, the Response’s Office of the Chief Medical Officer has collaborated with the CDC Office of Library Science to create a series called COVID-19 Science Update.
 
Percent of Delivered First Vaccine Doses Administered by U.S. States and Territories   
CDC has created a map to show the percentage of first doses of vaccines that have been administered in each jurisdiction from their supply. This information can be used to better understand how states are using their supply to initiate vaccination within their community.

Delta Variant: What We Know About the Science
This resource covered the latest updates from the CDC regarding the Delta variant.
 
Strategies for Increasing Adult Vaccination Rates
This video discusses new data from this nursing survey indicates access to PPE and the ability to communicate and implement changing policies have improved, while staffing shortages and the emotional health and well-being of nurse leaders have worsened.  The most recent August report also offers new insights into nurse leaders’ needs and tactics being used to address the growing staffing shortage. The report continues to identify a gap between roles, with focus on chief nursing officers, directors, and managers. 
 
Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States, January 2020–April 2021
Morbidity and Mortality Weekly Report (MMWR) detailing long-term symptoms among adults tested for SARS-CoV-2.

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021
On October 22, 2021, this report was posted online as an MMWR Early Release covering the Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During Delta Variant Predominance.
 
CDC/IDSA COVID-19 Clinician Call: COVID-19 Vaccine Boosters, the Immune Compromised & Protecting the Most Vulnerable
These one-hour webinars, held Saturdays at 3 p.m. ET, focus on timely issues of relevance to clinicians and feature case presentations by experts in the field, synthesis of new data, and an opportunity to engage with colleagues. Topics: COVID-19 Vaccine Boosters, the Immune Compromised & Protecting the Most Vulnerable.

CDC Expands COVID-19 Booster Recommendations – Media Statement
CDC has strengthened its recommendation on booster doses for individuals who are 18 years and older. Everyone ages 18 and older should get a booster shot either when they are 6 months after their initial Pfizer or Moderna series or 2 months after their initial J&J vaccine.
 
CDC Launches Global Networks, Innovative Research to Improve Detection and Response to Infectious Disease Threats
CDC launched two new global networks and several research projects, awarding $22 million to nearly 30 organizations around the world, to combat antimicrobial resistance (AR) and other healthcare threats through the establishment of two new networks: The Global Action in Healthcare Network (GAIHN) and the Global AR Laboratory and Response Network (Global AR Lab & Response Network). 
 
CDC Library: COVID-19 Science Update
The COVID-19 Science Update summarizes new and emerging scientific data for public health professionals to meet the challenges of this fast-moving pandemic. Weekly, staff from the CDC COVID-19 Response and the CDC Library systematically review literature in the WHO COVID-19 database, and select publications and preprints for public health priority topics in the CDC Science Agenda for COVID-19 and CDC COVID-19 Response Health Equity Strategy.
 
COCA Call: Molecular Approaches for Clinical and Public Health Applications to Detect Influenza and SARS-CoV-2 Viruses
The Clinician Outreach and Communication Activity (COCA) held a call Thursday, December 9, 2021. During this COCA Call, clinicians will learn critical information about molecular approaches for clinical and public health applications to detect the influenza virus and SARS-CoV-2, the virus that causes COVID-19. Presenters from CDC will review the most up to date guidance on clinical testing for influenza, including situations when influenza and SARS-CoV-2 are co-circulating in a community or other setting. In addition, presenters will provide in-depth discussion on cycle threshold (Ct) values from SARS-CoV-2 diagnostic assays and their correlation with viral load and infectiousness. Presenters will also discuss SARS-CoV-2 sequencing applications for public health.
 
In Conversation with the Surgeon General about COVID-19 Misinformation, Vaccines, Variants and More
On Nov. 30, U.S. Surgeon General, Vice Admiral Vivek H. Murthy, joined us for a webinar to talk about misinformation, children’s vaccines and boosters, and the role community organizations have in communicating trusted information across their communities. Learn more and watch the webinar. The Surgeon General released a step-by-step toolkit that provides specific guidance and resources for health care providers, educators, librarians, faith leaders and trusted community members to understand, identify and stop the spread of health misinformation in their communities.
 
Increasing Seasonal Influenza A (H3N2) Activity, Especially Among Young Adults and in College and University Settings, During SARS-CoV-2 Co-Circulation
CDC is issuing this Health Alert Network (HAN) Health Advisory about increased influenza A(H3N2) activity that could mark the beginning of the 2021-2022 influenza season. The purpose of this HAN Health Advisory is to:
 

  1. Remind public health practitioners and clinicians to recommend and offer the current seasonal influenza vaccine to all eligible persons aged six months and older (Flu vaccine and COVID-19 vaccine can be given at the same visit).
  2. Remind clinicians to consider testing for both influenza virus and SARS-CoV-2 in patients with influenza-like illness (ILI).
  3. Remind clinicians to consider testing for both influenza virus and SARS-CoV-2 in patients with influenza-like illness (ILI).

 
Morbidity and Mortality Weekly Report (MMWR) — SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021
A new variant of SARS-CoV-2 (the virus that causes COVID-19), B.1.1.529 (Omicron), was first reported to the World Health Organization (WHO) by South Africa on November 24, 2021. Omicron has numerous mutations with potential to increase transmissibility, confer resistance to therapeutics, or partially escape infection- or vaccine-induced immunity.
 
Omicron Variant: What You Need to Know
CDC has been collaborating with global public health and industry partners to learn about Omicron, as we continue to monitor its course. CDC has been using genomic surveillance throughout the course of the pandemic to track variants of SARS-CoV-2, the virus that causes COVID-19, and inform public health practice. We don’t yet know how easily it spreads, the severity of illness it causes, or how well available vaccines and medications work against it.
 
Science Brief: Community Use of Masks to Control the Spread of SARS-CoV-2
Updated Science Brief: Community Use of Masks to Control the Spread of SARS-CoV-2 — This webpage has recently been updated to include a section on mask wearing among children and data on the association of mask wearing with new infections, including infections related to SARS-CoV-2 variants of concern.
 
Science Brief: Omicron (B.1.1.529) Variant
On November 24, 2021, South Africa reported the identification of a new SARS-CoV-2 variant, B.1.1.529, to the World Health Organization (WHO). B.1.1.529 was first detected in specimens collected on November 11, 2021 in Botswana and on November 14, 2021 in South Africa.
 
What You Need to Know About Variants
CDC has been actively monitoring and preparing for this variant that has been detected in more than 20 countries. We will continue to work diligently with other U.S. and global public health and industry partners to learn more about this variant.  
 
New SARS-CoV-2 Variant of Concern Identified: Omicron (B.1.1.529) Variant
Omicron, a new SARS-CoV-2 variant, has been identified in many countries and categorized as a Variant of Concern by the U.S. government and the World Health Organization (WHO). Because little is known about Omicron currently, it is important for the public health and medical communities as well as the general public to remain vigilant to reduce potential exposure. This Health Alert Network (HAN) Health Advisory summarizes current knowledge about Omicron and provides recommendations on how to detect the Omicron variant within the United States as soon as possible to mitigate its spread.

CDC Resource: CDC Health Alert Network (HAN) Health Advisory: Rapid Increase of Omicron Variant Infections in the United States: Management of Healthcare Personnel with SARS-CoV-2 Infection or Exposure 
Due to the increased transmissibility of the SARS-CoV-2 Omicron variant and concerns about potential impacts on the healthcare system, the Centers for Disease Control and Prevention (CDC) is updating recommendations to enhance protection for healthcare personnel, patients, and visitors, and ensure adequate staffing in healthcare facilities. The guidance is based on the limited information currently available about the Omicron variant and will be updated as needed as new information becomes available. 

What We Know About Quarantine and Isolation — Why CDC Shortened Isolation and Quarantine for the General Population
COVID-19 cases due to the Omicron variant have increased along with seasonal increases in influenza and other respiratory virus infections. The potential for a large number of cases raises serious concerns about societal impact due to illness, as well as isolation and quarantine requirements [1]. CDC has been monitoring the emerging science on when and for how long a person is maximally infectious with Omicron, as well as the effectiveness of COVID-19 vaccines and booster doses against Omicron infection. Data related to the mental health effects of the pandemic and adherence to prevention interventions have also been considered.
 
CDC Recommends Pfizer Booster at 5 Months, Additional Primary Dose for Certain Immunocompromised Children
CDC is updating our recommendation for when many people can receive a booster shot, shortening the interval from 6 months to 5 months for people who received the Pfizer-BioNTech COVID-19 Vaccine. This means that people can now receive an mRNA booster shot 5 months after completing their Pfizer-BioNTech primary series. The booster interval recommendation for people who received the J&J vaccine (2 months) or the Moderna vaccine (6 months), has not changed.


Estimated Time:

Categories: Disaster, Infection,
Content Type: External Resource,